Comera Life Sciences Holdings Inc Quick Ratio (CMRA) starting from the third quarter 2023 to third quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Comera Life Sciences Holdings Inc   (NASDAQ: CMRA)

Comera Life Sciences Holdings Inc 's Quick Ratio

CMRA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Comera Life Sciences Holdings Inc 's Cash & cash equivalent grew by 248.62 % in the Q3 2023 sequentially, while Current Liabilities decreased, this led to improvement in Comera Life Sciences Holdings Inc 's Quick Ratio to 0.62, Quick Ratio remained below Comera Life Sciences Holdings Inc average.

Within Major Pharmaceutical Preparations industry 467 other companies have achieved higher Quick Ratio than Comera Life Sciences Holdings Inc in third quarter 2023. While Quick Ratio total ranking has improved so far during the Q3 2023 to 2679, from total ranking in the second quarter 2023 at 3112.

Explain Quick Ratio?
How much Cash & cash equivalents CMRA´s has?
What are CMRA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CMRA Quick Ratio (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3
Y / Y Current Liabilities Change -9.35 % 69.5 % 263.29 % 2374.9 % -
Y / Y Cash & cash equivalent Change -33.23 % -89.57 % -75.82 % 161.09 % -
Quick Ratio MRQ 0.62 0.13 0.47 0.1 0.84
CMRA's Total Ranking # 2679 # 3112 # 1902 # 3601 # 2127
Seq. Current Liabilities Change -25.83 % 17.84 % -33.68 % 56.38 % 38.69 %
Seq. Cash & cash equivalent Change 248.62 % -67.16 % 222.95 % -81.94 % -45.55 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 468
Healthcare Sector # 867
Overall Market # 2679


Quick Ratio Statistics
High Average Low
7.08 1.54 0.1
(Dec 31 2021)   (Dec 31 2022)




Financial Statements
Comera Life Sciences Holdings Inc 's Current Liabilities $ 3 Millions Visit CMRA's Balance sheet
Comera Life Sciences Holdings Inc 's Cash & cash equivalent $ 2 Millions Visit CMRA's Balance sheet
Source of CMRA's Sales Visit CMRA's Sales by Geography


Cumulative Comera Life Sciences Holdings Inc 's Quick Ratio

CMRA's Quick Ratio for the trailling 12 Months

CMRA Quick Ratio

 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 128.51 % 350.87 % 1139.56 % 5550.47 % -
Y / Y Cash & cash equivalent TTM Growth -69.48 % -54.72 % 45.12 % 7750.03 % -
Quick Ratio TTM 0.29 0.34 0.7 1.28 2.15
Total Ranking TTM # 4643 # 4018 # 3959 # 2432 # 0
Seq. Current Liabilities TTM Growth -1.94 % 11.59 % 21.05 % 72.5 % 93.48 %
Seq. Cash & cash equivalent TTM Growth -17 % -45.69 % -33.68 % 2.1 % 23.16 %

Quick ratio ranking by company, industry and sector >> Back to CMRA Financial Strength Comparisons >> Go to Compare CMRA Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in CMRA's Current Liabilities to $2.93 millions, cumulative Quick Ratio to 0.29 below the CMRA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 575 other companies have achieved higher Quick Ratio than Comera Life Sciences Holdings Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 4018 to 4643.

Explain Quick Ratio?
How much Cash & cash equivalents CMRA´s has?
What are CMRA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 576
Healthcare Sector # 1166
Within the Market # 4643


trailing twelve months Quick Ratio Statistics
High Average Low
1.22 0.63 0.29
(Dec 31 2022)   (Sep 30 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Avalo Therapeutics Inc   1.70 $ 10.181  Millions$ 6.005  Millions
Equillium Inc   1.67 $ 46.306  Millions$ 27.771  Millions
Amicus Therapeutics inc   1.65 $ 280.300  Millions$ 169.454  Millions
Acadia Pharmaceuticals Inc   1.65 $ 345.920  Millions$ 209.603  Millions
Biovie Inc   1.61 $ 21.215  Millions$ 13.212  Millions
Gri Bio Inc   1.60 $ 3.488  Millions$ 2.177  Millions
Palvella Therapeutics Inc   1.55 $ 44.810  Millions$ 28.866  Millions
Bgm Group Ltd  1.55 $ 8.476  Millions$ 5.481  Millions
Quantum Cyber N v   1.54 $ 16.391  Millions$ 10.665  Millions
Pfizer Inc  1.53 $ 44,181.000  Millions$ 28,932.000  Millions
Organigram Global Inc   1.51 $ 25.940  Millions$ 17.182  Millions
Nanobiotix S a   1.51 $ 84.317  Millions$ 55.858  Millions
Novo Nordisk A  1.50 $ 4,278.051  Millions$ 2,853.453  Millions
Atreca inc   1.50 $ 21.388  Millions$ 14.302  Millions
Affimed N v   1.49 $ 43.152  Millions$ 29.016  Millions
Igc Pharma Inc   1.48 $ 3.124  Millions$ 2.106  Millions
Maia Biotechnology Inc   1.47 $ 6.105  Millions$ 4.150  Millions
Mannkind Corporation  1.46 $ 141.016  Millions$ 96.374  Millions
Neximmune Inc   1.45 $ 9.000  Millions$ 6.205  Millions
Ani Pharmaceuticals Inc  1.44 $ 193.078  Millions$ 134.352  Millions
Wave Life Sciences Ltd   1.40 $ 139.942  Millions$ 99.980  Millions
Petros Pharmaceuticals inc   1.39 $ 17.970  Millions$ 12.934  Millions
Transcode Therapeutics Inc   1.35 $ 7.565  Millions$ 5.598  Millions
Universe Pharmaceuticals Inc  1.35 $ 18.504  Millions$ 13.754  Millions
Addex Therapeutics Ltd  1.34 $ 4.599  Millions$ 3.442  Millions
2seventy Bio Inc   1.33 $ 90.226  Millions$ 68.008  Millions
Cytomx Therapeutics Inc   1.32 $ 194.110  Millions$ 146.790  Millions
Scisparc Ltd  1.32 $ 2.076  Millions$ 1.571  Millions
Elicio Therapeutics Inc   1.29 $ 14.841  Millions$ 11.486  Millions
Rigel Pharmaceuticals Inc  1.29 $ 62.351  Millions$ 48.273  Millions

Date modified: 2026-09-08T15:11:07+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.